半夏白术天麻汤治疗高血压:荟萃分析与网络药理学整合研究
本研究通过荟萃分析与网络药理学评价半夏白术天麻汤(BXD)治疗高血压的疗效与潜在机制。荟萃分析纳入23项研究共2041例患者,显示BXD联合常规治疗可改善临床有效率、血压、血脂、同型半胱氨酸、内皮功能、炎症及中医症状积分,且安全性好;网络药理学提示降压靶点可能涉及AKT1、NOS3、ACE和PPARG,活性成分可能包括柚皮素、茯苓酸C、齿孔酸和甘草查尔酮B。
要点
- BXD联合常规治疗可改善高血压患者血压、血脂及内皮功能等指标。
- BXD联合治疗安全性好,未见明显不良反应。
- 网络药理学提示BXD降压靶点可能为AKT1、NOS3、ACE和PPARG。
核心结论
- Meta分析提示BXD联合常规治疗对高血压患者多项指标有益且安全,但受纳入研究方法学质量差和样本量小的影响,疗效与安全性仍需高质量临床研究进一步验证。
研究设计与样本
- 研究采用荟萃分析与网络药理学相结合的方法,荟萃分析纳入23项研究共2041例患者,系统评价注册号CRD42022353666。
主要发现
- 与常规治疗相比,BXD联合治疗有助于改善临床有效率、血压、血脂、同型半胱氨酸、内皮功能、炎症及中医症状积分。
- Meta分析显示BXD安全且无明显不良反应。
- 网络药理学显示BXD的降压靶点可能为AKT1、NOS3、ACE和PPARG,降压活性成分可能为柚皮素、茯苓酸C、齿孔酸和甘草查尔酮B。
临床怎么用
- 在常规降压治疗基础上,可考虑联合BXD以改善血压、血脂、内皮功能及中医症状,但需结合患者具体情况并关注研究证据的局限性。
局限性
- 纳入的中国研究方法学质量较差,且大多数样本量小,分析结果可能受偏倚影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypertension is a major cardiovascular risk factor, which seriously affects the quality of life of patients. Banxia Baizhu Tianma Decoction (BXD) is a Chinese herbal formula that is widely used to treat hypertension in China. This study aimed to evaluate the efficacy and potential mechanism of BXD for hypertension by meta-analysis and network pharmacology. Meta-analysis was performed to explore the efficacy and safety of BXD combined with conventional treatment for hypertension. Network pharmacology was used to explore the molecular mechanism of BXD in antihypertension. A total of 23 studies involving 2,041 patients were included. Meta-analysis indicated that compared with conventional treatment, combined BXD treatment was beneficial to improve clinical efficacy rate, blood pressure, blood lipids, homocysteine, endothelial function, inflammation, and traditional Chinese medicine symptom score. In addition, meta-analysis indicated that BXD is safe and has no obvious adverse reactions. Network pharmacology showed that the antihypertensive targets of BXD may be AKT1, NOS3, ACE, and PPARG. The antihypertensive active ingredients of BXD may be naringenin, poricoic acid C, eburicoic acid, and licochalcone B. Due to the poor methodological quality of the Chinese studies and the small sample size of most, the analysis of this study may have been affected by bias. Therefore, the efficacy and safety of BXD for hypertension still need to be further verified by high-quality clinical studies. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022353666.
引用
- Lin J, Wang Q, Xu S, et al. Banxia baizhu tianma decoction, a Chinese herbal formula, for hypertension: Integrating meta-analysis and network pharmacology. Front Pharmacol. 2022. PMID: 36534045. doi:10.3389/fphar.2022.1025104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。